Accessibility Menu
SomnoMed logo

SomnoMed(ASX) SOM

Market CapA$89.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-86%
5 Year-84%
1 Year-52%
1 Month-20%
A$0.37
-8.64%
-0.04Today
SomnoMed last closing stock price
MetricPriceDate
Last closeAUD 0.372026-08-13
SomnoMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.9%AUD 0.422026-08-06
1 month-19.57%AUD 0.462026-07-14
3 month-35.09%AUD 0.572026-05-15
Year to date-52.07%AUD 0.772025-12-30
1 year-51.95%AUD 0.772025-08-12
3 year-59.78%AUD 0.922023-08-11
5 year-84.19%AUD 2.342021-08-13
Since inception-86.06%AUD 2.912004-08-27

SomnoMed Financials at a Glance

Market Cap

A$89.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$218.75M

Net Income (TTM)

-A$8.56M

EPS (TTM)

-A$0.01

P/E Ratio

-34.03

Dividend

A$0.00

Beta (Volatility)

-0.16 (Low)

Price

A$0.37

Volume

0

Open

A$0.38

Previous Close

A$0.37

Daily Range

A$0.37 - A$0.38

52-Week Range

A$0.37 - A$0.95

Estimated Earnings Date

Aug 27, 2026

SOM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SomnoMed

SomnoMed Limited is a healthcare company specializing in the production and sale of oral devices for the treatment of sleep-related disorders. The company operates in the Asia Pacific region, North America, and Europe, focusing on innovative solutions for obstructive sleep apnea and other related conditions.

Products and Services
  • SomnoDent devices for obstructive sleep apnea treatment
  • SomMorning Repositioner for jaw alignment
  • SomTabs cleaning tablets for oral appliances
Growth Outlook
  • Revenue increased to AUD 60.7 million in the latest quarter
  • Gross profit margin improved to 57.4% over the trailing twelve months
  • Expansion into new markets is expected to drive future growth
Financial Highlights
  • Net income of AUD 792,000 reported in the latest quarter
  • Operating income margin reached 4.6% in Q2 2025
  • Cash and cash equivalents totaled AUD 18 million as of December 2025
SomnoMed Limited has established itself as a key player in the medical devices sector, particularly in the treatment of sleep disorders. The company's diverse product offerings, including various SomnoDent devices, cater to a growing market of patients seeking effective solutions for obstructive sleep apnea. Recent financial performance indicates a positive trend, with a notable increase in revenue and improvements in gross profit margins. The company is well-positioned for future growth, particularly as it expands into new markets and continues to innovate its product line. With a solid cash position, SomnoMed Limited is poised to capitalize on emerging opportunities in the healthcare sector.
AI Generated • Jul 18, 2026

Industry

Healthcare Equipment and Supplies

CEO

Amrita Blickstead, MBA; Karen Borg

Headquarters

Crows Nest, NSW 2065, AU

SOM Financials

Key Financial Metrics (TTM)

Gross Margin

57.40%

Operating Margin

2.35%

Net Income Margin

-2.16%

Return on Equity

-5.31%

Return on Capital

6.65%

Return on Assets

-3.20%

Earnings Yield

-2.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$89.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

219.77M

Volume

0

Avg. Volume

125.55K

Financials (TTM)

Gross Profit

A$125.31M

Operating Income

A$2.10M

EBITDA

A$5.62M

Operating Cash Flow

A$10.17M

Capital Expenditure

-A$5.66M

Free Cash Flow

A$4.51M

Cash & ST Invst.

A$18.03M

Total Debt

A$14.01M

SomnoMed Performance Analysis

SomnoMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 72,580,403N/A
20232023-06-30AUD 83,616,16415.2%
20242024-06-30AUD 91,651,0699.6%
20252025-06-30AUD 111,492,94121.6%
SomnoMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-303.2%
Q22024-12-3115.4%
Q42025-06-307.6%
Q22025-12-315.1%
SomnoMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.04N/A
20232023-06-30AUD -0.0880.4%
20242024-06-30AUD -0.1034.5%
20252025-06-30AUD -0.02-83.9%
SomnoMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-307.0%
Q22024-12-3198.2%
Q42025-06-30-1644.4%
Q22025-12-31122.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$60.72M

+34.6%

Gross Profit

A$34.39M

+39.6%

Gross Margin

56.64%

N/A

Market Cap

A$89.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$296.69K

N/A

Employees

300

N/A

Net Income

A$792.00K

+112.5%

EBITDA

A$5.66M

+592.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$18.03M

+40.4%

Total Debt

A$14.01M

-33.5%

Accounts Receivable

A$18.15M

+44.5%

Inventory

A$7.60M

+57.4%

Long Term Debt

A$7.77M

-50.4%

Short Term Debt

A$6.24M

+15.7%

Return on Assets

-3.20%

N/A

Return on Invested Capital

5.06%

N/A

Free Cash Flow

A$1.77M

+126.1%

Operating Cash Flow

A$4.15M

+190.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AHC.AXAustco Healthcare Limited
A$0.23+0.00%
PAR.AXParadigm Biopharmaceuticals Limited
A$0.18+2.86%
LDX.AXLumos Diagnostics Holdings Limited
A$0.12+0.00%
ONE.AXOneview Healthcare PLC
A$0.16+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.56+0.02%
CDECoeur Mining
$18.45-0.02%
TAT&T
$24.58+0.01%
SMRNuScale Power
$9.85+0.03%

Questions About SOM

What is the current price of SomnoMed?

SomnoMed is trading at A$0.37 per share.

What is the 52-week range for SomnoMed?

Over the past 52 weeks, SomnoMed has traded between A$0.37 and A$0.95.

How much debt does SomnoMed have?

As of the most recent reporting period, SomnoMed reported total debt of A$8.03M.

How much cash does SomnoMed have on hand?

SomnoMed reported A$17.29M in cash and cash equivalents in its most recent financial results.

What is SomnoMed’s dividend yield?

SomnoMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.